SCHEMBL6317246

SCHEMBL6317246

Cc1[nH]c2ccc(CCN3CCCC3)cc2c1C(=O)OC(C)c1ccc(Cl)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALOX15 P16050 2/20 0.38
SIGMAR1 Q99720 1/20 0.37
CNR2 P34972 1/20 0.37
MAPT P10636 1/20 0.37
ALOX5 P09917 2/20 0.36
AVPR1B P47901 1/20 0.36
CNR1 P21554 2/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316063 0.99 HPGD (0.41) ALDH1A1KMT2AMEN1POLBHPGD
SCHEMBL6323321 0.92 AVPR1B (0.38) ALDH1A1HPGDLMNASMN1; SMN2MAPT
SCHEMBL6321137 0.90 ALDH1A1 (0.41) ALDH1A1KMT2AHPGDLMNASMN1; SMN2
SCHEMBL6322911 0.90 KMT2A (0.41) ALDH1A1KMT2AMEN1POLBHPGD
SCHEMBL6322706 0.88 LMNA (0.41) ALDH1A1KMT2AMEN1POLBHPGD
SCHEMBL6324066 0.88 TSHR (0.41) ALDH1A1KMT2AMEN1POLBLMNA
SCHEMBL6316848 0.86 LMNA (0.41) ALDH1A1KMT2AMEN1POLBHPGD
SCHEMBL6316870 0.86 ALOX15 (0.45) ALDH1A1KMT2AHPGDLMNASMN1; SMN2
SCHEMBL6320492 0.85 LMNA (0.40) ALDH1A1KMT2AMEN1HPGDLMNA
SCHEMBL6315195 0.85 ALOX15 (0.45) ALDH1A1KMT2APOLBHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US claimed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US claimed
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
EP-1377549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR Millennium Pharmaceuticals, Inc. (US) 2004-01-07 EP disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 ALDH1A1 672/4885KMT2A 4021/4885MEN1 4058/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 ALDH1A1 956/4885KMT2A 3935/4885MEN1 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.